TY - JOUR
T1 - Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction
AU - Tissot, Adrien
AU - Durand, Eugénie
AU - Goronflot, Thomas
AU - Coiffard, Benjamin
AU - Renaud-Picard, Benjamin
AU - Roux, Antoine
AU - Demant, Xavier
AU - Mornex, Jean-François
AU - Falque, Loïc
AU - Salpin, Mathilde
AU - le Pavec, J. rôme
AU - Villeneuve, Thomas
AU - Boussaud, V. ronique
AU - Knoop, Christiane
AU - Magnan, Antoine
AU - Lair, David
AU - Berthelot, Laureline
AU - Danger, Richard
AU - Brouard, Sophie
AU - Blanchard, Elodie
AU - Demant, Xavier
AU - Hulo, Virginie
AU - the COLT consortium
AU - Ruiz-Patino, Maria
AU - Kuylen, Maarten Vander
AU - Sokolow, Youri
AU - Stefanidis, Constantin
AU - Huybrechts, Isabelle
AU - Perrin, Laurent
AU - Taccone, Fabio
AU - Etienne, Isabelle
AU - Blanchard, Elodie
AU - Roussoulières, Anna
AU - Hites, Maya
AU - Lambert, Agnes
AU - Hemelsoet, Axelle
AU - Bedouch, Pierrick
AU - Briault, Amandine
AU - Falque, Loic
AU - Perrier, Quentin
AU - Raymond, Christel Saint
AU - Chacaroun, Samarmar
AU - Gioria, Yoann
AU - Quentin, Joane
AU - Grima, Renaud
AU - Drevet, Gabrielle
AU - Maury, Jean-Michel
AU - Tronc, François
AU - Portan, Philippe
AU - Mornex, Jean-François
AU - Yeremenko, Nataliya
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - Background: Long-term outcomes of lung transplantation (LTx) remain hampered by chronic lung allograft dysfunction (CLAD). Matrix metalloproteinase 9 (MMP-9) is a secretory endopeptidase identified as a key mediator in fibrosis processes associated with CLAD. The objective of this study was to investigate whether plasma MMP9 levels may be prognostic of CLAD development. Methods: Participants were selected from the Cohort in Lung Transplantation (COLT) for which a biocollection was associated. We considered two time points, year 1 (Y1) and year 2 (Y2) post-transplantation, for plasma MMP-9 measurements. We analysed stable recipients at those time points, comparing those who would develop a CLAD within the 2 years following the measurement to those who would remain stable 2 years after. Results: MMP-9 levels at Y1 were not significantly different between the CLAD and stable groups (230 ng/ml vs. 160 ng/ml, p = 0.4). For the Y2 analysis, 129 recipients were included, of whom 50 developed CLAD within 2 years and 79 remained stable within 2 years. MMP-9 plasma median concentrations were higher in recipients who then developed CLAD than in the stable group (230 ng/ml vs. 118 ng/ml, p = 0.003). In the multivariate analysis, the Y2 MMP-9 level was independently associated with CLAD, with an average increase of 150 ng/ml (95% CI [0–253], p = 0.05) compared to that in the stable group. The Y2 ROC curve revealed a discriminating capacity of blood MMP-9 with an area under the curve of 66%. Conclusion: Plasmatic MMP-9 levels measured 2 years after lung transplantation have prognostic value for CLAD.
AB - Background: Long-term outcomes of lung transplantation (LTx) remain hampered by chronic lung allograft dysfunction (CLAD). Matrix metalloproteinase 9 (MMP-9) is a secretory endopeptidase identified as a key mediator in fibrosis processes associated with CLAD. The objective of this study was to investigate whether plasma MMP9 levels may be prognostic of CLAD development. Methods: Participants were selected from the Cohort in Lung Transplantation (COLT) for which a biocollection was associated. We considered two time points, year 1 (Y1) and year 2 (Y2) post-transplantation, for plasma MMP-9 measurements. We analysed stable recipients at those time points, comparing those who would develop a CLAD within the 2 years following the measurement to those who would remain stable 2 years after. Results: MMP-9 levels at Y1 were not significantly different between the CLAD and stable groups (230 ng/ml vs. 160 ng/ml, p = 0.4). For the Y2 analysis, 129 recipients were included, of whom 50 developed CLAD within 2 years and 79 remained stable within 2 years. MMP-9 plasma median concentrations were higher in recipients who then developed CLAD than in the stable group (230 ng/ml vs. 118 ng/ml, p = 0.003). In the multivariate analysis, the Y2 MMP-9 level was independently associated with CLAD, with an average increase of 150 ng/ml (95% CI [0–253], p = 0.05) compared to that in the stable group. The Y2 ROC curve revealed a discriminating capacity of blood MMP-9 with an area under the curve of 66%. Conclusion: Plasmatic MMP-9 levels measured 2 years after lung transplantation have prognostic value for CLAD.
UR - http://www.scopus.com/inward/record.url?scp=85184719474&partnerID=8YFLogxK
U2 - 10.1186/s12931-024-02707-3
DO - 10.1186/s12931-024-02707-3
M3 - Article
C2 - 38336710
SN - 1465-9921
VL - 25
JO - Respiratory research
JF - Respiratory research
IS - 1
M1 - 88
ER -